Copyright ©The Author(s) 2017.
World J Clin Oncol. Apr 10, 2017; 8(2): 100-105
Published online Apr 10, 2017. doi: 10.5306/wjco.v8.i2.100
Table 1 Phase III clinical trials evaluating approved drugs in second and subsequent treatment lines for metastatic renal cell carcinoma
AxitinibCabozantinibLenvatinib + EverolimusNivolumab
Trial designPhase IIIPhase IIIPhase IIPhase III
Patient population2nd Line (100%)2L- 71%2nd Line (100%)2L- 72%
3L- 29%3L- 28%
MSKCC risk % (Good/int/poor)28/37/3345/42/1224/37/3935/49/16
ORR% (ICR)19%17%35%22%
Progression disease (%)22%12%4%35%
PFS (m)6.7 (HR 0.66)7.4 (HR 0.51)12.8 (HR 0.40)4.6 (HR 0.88)
PFS (m) in pts with bone metsNR7.4 (HR 0.33)NRNR
OS (m)20.1 (HR 0.96)21.4 (HR 0.66)25.5 (HR 0.59)25.0 (HR 0.73)
Dose reductions30%60%71%N/A
Discontinuations due to AEs7%9%25%8%
Toxicity G3/4 (%)56%68%71%19%
Average monthly cost (US basis)9580$10229$22461$12435$